Iter Investments
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Iter Investments.
Key people at Iter Investments.
Iter Investments is a venture capital firm dedicated to transforming mental and behavioral health by backing breakthrough companies in the alternative therapeutics ecosystem, with a strong focus on psychedelics. Its mission is to support innovative startups that are redefining how mental health conditions are treated—moving beyond traditional pharmaceuticals toward more holistic, science-backed, and often psychedelic-assisted modalities. The firm invests primarily at the seed and Series A stages, targeting early-stage companies in health tech, biotechnology, therapeutics, consumer health, wellness, and psychedelic-enabled mental health platforms.
By concentrating on the emerging psychedelic and alternative therapeutics industry, Iter Investments plays a catalytic role in a rapidly evolving startup ecosystem. It helps de-risk and scale companies that are tackling some of the most pressing global health challenges—depression, anxiety, addiction, and trauma—while also advancing the legitimacy and accessibility of psychedelic medicine. Through strategic capital allocation and deep domain expertise, Iter is shaping the next generation of mental health infrastructure, from clinical platforms and retreats to data, media, and investment tools that support the broader ecosystem.
---
Iter Investments emerged in the early 2020s as part of a broader wave of investor interest in psychedelic science and mental health innovation. Founded and based in Florida, the firm was built by a multidisciplinary team of builders, investors, scientists, physicians, clinicians, lawyers, and technologists who shared a conviction: that the future of mental and behavioral health lies in alternative, often psychedelic-based, therapeutic models. The name “Iter” reflects this vision—derived from the Latin word for “pathway” or “journey,” and also referencing the cerebral aqueduct in the brain, symbolizing the passage between old and new paradigms in mental healthcare.
From the outset, Iter positioned itself not just as a capital provider but as a builder within the psychedelic ecosystem. Rather than passively investing, the team actively shaped infrastructure by launching Nucleus Holding, a holding company that incubates key ecosystem assets like Psychedelic Invest (a leading media and investment intelligence platform) and Neuly (a comprehensive psychedelic data and insights database). This builder mentality, combined with deep clinical and operational expertise, allowed Iter to move quickly in a nascent, complex, and highly regulated space, establishing itself as a trusted partner for founders pioneering the future of mental health.
---
---
Iter Investments sits at the intersection of three powerful trends: the mental health crisis, the resurgence of psychedelic science, and the digitization of behavioral health. Globally, demand for mental health solutions is surging, yet traditional treatments remain inadequate for millions. At the same time, clinical research has validated the therapeutic potential of psychedelics like psilocybin, MDMA, and ketamine, creating a new frontier for innovation. Iter is positioned at the epicenter of this shift, backing companies that are building the tools, platforms, and experiences that will define the next era of mental healthcare.
The firm is also helping to professionalize and legitimize the psychedelic industry. By funding science-backed retreats (like Beckley Retreats), clinical-grade PsyTech platforms, and robust data and media infrastructure, Iter is reducing noise and increasing credibility in a space that has historically struggled with hype and regulatory uncertainty. As regulators in the U.S. and Europe move toward approving psychedelic-assisted therapies, Iter’s portfolio companies are well-positioned to become key players in the commercial rollout.
Moreover, Iter’s work reflects a broader trend in venture capital: the rise of “ecosystem investors” who don’t just fund startups but actively build the infrastructure that enables an entire industry to scale. In this sense, Iter is less like a traditional VC and more like a strategic architect of the psychedelic and alternative therapeutics landscape.
---
Iter Investments is poised to become one of the defining venture firms in the alternative therapeutics space. As psychedelic-assisted therapies move closer to mainstream adoption, the companies and infrastructure Iter has backed—from clinical platforms and retreats to data and media—will become increasingly valuable. The firm’s early, concentrated bet on psychedelics, combined with its builder mentality, gives it a structural advantage over generalist funds that entered the space later.
Looking ahead, Iter is likely to deepen its focus on the full mental health value chain: from drug development and clinical delivery to digital therapeutics, community, and long-term wellness. It may also expand its fund strategy to include later-stage or sector-specific vehicles as the ecosystem matures. The success of its portfolio companies, especially those at the intersection of psychedelics and technology, could influence how investors, regulators, and healthcare systems think about mental health innovation.
In a world where mental health is no longer a side issue but a central challenge of our time, Iter Investments is not just funding startups—it’s helping to forge the pathway to a new paradigm of healing.
Key people at Iter Investments.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 1, 2021 | Psilera | $3.0M Seed | — | — |
